MRI + PET/CT: A Safer, Accurate Way to Stage Esophageal Cancer

Technology Innovation /

A new study shows that combining MRI with PET/CT can stage esophageal cancer (EC) as accurately as the current standard methods while being less invasive and reducing radiation exposure. Currently, staging relies on contrast-enhanced CT, endoscopic ultrasound (EUS), and PET/CT, which require radiation, anesthesia, and may be limited if the tumor obstructs the esophagus. In a […]

MRI + PET/CT: A Safer, Accurate Way to Stage Esophageal Cancer Read More »

Pirtobrutinib Offers New Hope for Hard-to-Treat CLL and SLL

Treatment /

Pirtobrutinib is a new therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), especially in patients who have received multiple prior treatments. Unlike older BTK inhibitors, pirtobrutinib is a selective, noncovalent BTK inhibitor that binds reversibly and remains effective against the common C481S mutation causing resistance. In the Phase 1/2 BRUIN trial, it achieved an

Pirtobrutinib Offers New Hope for Hard-to-Treat CLL and SLL Read More »

PARP Inhibitors in Prostate Cancer: A Clinical Trial Analysis

Clinical Trails /

Global trials are showing strong promise for PARP inhibitors as a new targeted treatment for advanced prostate cancer. Prostate cancer is the second most common cancer in men, with about 1.5 million new cases yearly and numbers expected to rise to 2.4 million by 2040. While early-stage prostate cancer has nearly a 100% 5-year survival

PARP Inhibitors in Prostate Cancer: A Clinical Trial Analysis Read More »

Durvalumab Combo Delivers Lasting Survival Gains in Advanced Biliary Tract Cancer

Treatment /

The updated results from the Phase III TOPAZ-1 trial, with a median follow-up of about 41 months, provide the longest data yet for durvalumab combined with gemcitabine and cisplatin in advanced biliary tract cancer. The study continues to show a strong and lasting survival benefit for patients receiving the immunotherapy combination compared to standard chemotherapy

Durvalumab Combo Delivers Lasting Survival Gains in Advanced Biliary Tract Cancer Read More »

New Discovery Uncovers Key Mechanism Behind Drug Resistance in HER2-Positive Breast Cancer

Research Advances /

Researchers have identified a key mechanism behind drug resistance in some HER2-positive breast cancers treated with antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd). The culprit is p95HER2, a truncated form of HER2 that alters cellular signaling and creates an immune-protected tumor microenvironment, preventing ADCs from effectively killing cancer cells. Preclinical studies showed that neratinib, a pan-HER

New Discovery Uncovers Key Mechanism Behind Drug Resistance in HER2-Positive Breast Cancer Read More »

Personalized Approaches Redefine Treatment for Metastatic Pancreatic Cancer

Treatment /

Metastatic pancreatic cancer treatment is increasingly personalized, considering tumor biology, patient health, and treatment goals. Assessing comorbidities, nutrition, and performance status helps guide therapy intensity, while molecular testing—including BRCA and RAS mutations—identifies actionable targets. The FDA-approved NALIRIFOX regimen (liposomal irinotecan, oxaliplatin, 5-FU, leucovorin) demonstrated improved outcomes over gemcitabine plus nab-paclitaxel in the NAPOLI 3 trial. Compared

Personalized Approaches Redefine Treatment for Metastatic Pancreatic Cancer Read More »

AI Tool Mirai Shows Promise in Early Detection of Interval Breast Cancers

Technology Innovation /

Recent study evaluated the AI deep-learning model Mirai for predicting interval breast cancers (ICs)—cancers that appear between scheduled mammogram screenings—in a screening program for women aged 50–70. The study analyzed 134,217 negative screening mammograms, including 524 ICs. Mirai’s 3-year risk scores were significantly higher in women who later developed ICs, with an overall C index

AI Tool Mirai Shows Promise in Early Detection of Interval Breast Cancers Read More »

Fibroblast-Lactate Signaling Identified as Key Driver of Chemoresistance in Colorectal Cancer

Research Advances /

Researchers have uncovered a key mechanism by which cancer-associated fibroblasts (CAFs) drive oxaliplatin resistance and stemness in colorectal cancer (CRC) through the CAF–lactate–ANTXR1 axis. A glycolytically active CAF subset (resCAFs) produces excess lactate via high MCT4 and LDHA expression, which modifies cancer cell behavior. Lactate induces histone lactylation (H3K18la), activating ANTXR1 transcription, and directly lactylates ANTXR1 at lysine 453. This

Fibroblast-Lactate Signaling Identified as Key Driver of Chemoresistance in Colorectal Cancer Read More »

Pembrolizumab Improves Survival in Locally Advanced Head and Neck Cancer

Treatment /

Pembrolizumab (Keytruda) has been approved for use before and after surgery in adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS ≥1). The treatment plan includes pembrolizumab alone before surgery, followed by pembrolizumab with standard radiation therapy (with or without cisplatin) after surgery, and continued pembrolizumab afterward.

Pembrolizumab Improves Survival in Locally Advanced Head and Neck Cancer Read More »

Vepugratinib Shows Promise as Treatment for Advanced FGFR3-Positive Urothelial Cancer

Treatment /

The phase 1 FORAGER-1 trial tested vepugratinib (LY3866288), a selective oral FGFR3 inhibitor, in metastatic urothelial carcinoma (mUC) patients with FGFR3 alterations (15–20% of cases). Unlike older pan-FGFR inhibitors, vepugratinib targets FGFR3 specifically to reduce off-target toxicity. As a single agent, 200 mg twice daily showed the best balance of efficacy and safety, producing a 34% overall

Vepugratinib Shows Promise as Treatment for Advanced FGFR3-Positive Urothelial Cancer Read More »